(Q44815426)

6 December 2017

More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin (English)

1 reference

6 December 2017

1 reference

1 reference

5

1 reference

6 December 2017

Lev M Berstein

1

1 reference

6 December 2017

Marina P Boyarkina

series ordinal

2

1 reference

6 December 2017

Evgenia V Tsyrlina

series ordinal

3

1 reference

6 December 2017

Elena A Turkevich

series ordinal

4

1 reference

6 December 2017

20 May 2010

1 reference

6 December 2017

1 reference

6 December 2017

28

1 reference

6 December 2017

4

1 reference

6 December 2017

1260-1263

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-010-9572-6

6 December 2017

0 references

cites work

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Insulin-lowering effects of metformin in women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Targeting AMPK: a new therapeutic opportunity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Metformin, insulin, breast cancer and more...

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Problems and solutions in the evaluation of hormone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Sulphonylureas and cancer: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Metformin in breast cancer: time for action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Is it time to test metformin in breast cancer clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9572-6

Genotoxic factors associated with the development of receptor-negative breast cancer: potential role of the phenomenon of switching of estrogen effects

21 January 2018

1 reference

12 December 2020

Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels.

1 reference

12 December 2020

Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase

1 reference

12 December 2020

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

1 reference

12 December 2020

Breast cancer receptor status in smoking and diabetic patients

1 reference

12 December 2020

Immunohistochemical assessment of hormone receptor status using a new scoring system (J-Score) in breast cancer

1 reference

12 December 2020

Dietary treatment of diabetes mellitus

1 reference

12 December 2020

Association between diabetes mellitus and adverse characteristics of breast cancer at presentation

1 reference

12 December 2020

10.1007/S12032-010-9572-6

Identifiers

DOI

1 reference

6 December 2017

1 reference